{"title":"66例晚期口腔鳞状细胞癌颈部淋巴结转移患者行逆行超选择性动脉灌注热放化疗的回顾性研究","authors":"Toshiyuki Koizumi , Takashi Ohya , Masaki Iida , Yuichiro Hayashi , Senri Oguri , Toshinori Iwai , Mitomu Kioi , Kenji Mitsudo","doi":"10.1016/j.ajoms.2025.06.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>A retrospective study of 66 patients with oral squamous cell carcinoma<span><span> was conducted, focusing on the outcomes and treatment-related adverse events of retrograde superselective intra-arterial </span>chemoradiotherapy<span> combined with hyperthermia on metastatic lymph nodes.</span></span></div></div><div><h3>Methods</h3><div><span>The superficial temporal and occipital arteries were catheterized. The treatment consisted of superselective intra-arterial chemotherapy (docetaxel, 60 mg/m</span><sup>2</sup><span>; cisplatin, 150 mg/m</span><sup>2</sup><span>) and daily concurrent radiotherapy (60 Gy) combined with hyperthermia for 6 weeks. Hyperthermia was induced once or twice weekly for 50 min during chemoradiotherapy.</span></div></div><div><h3>Results</h3><div>The 3-year locoregional control and overall survival<span><span> rates were 82 % and 78 %, respectively. Treatment-related adverse events included grade 3 and 4 oral mucositis in 97 % of patients, </span>radiation dermatitis in 50 %, and grade 1 and 2 neck skin burns in 59 % of patients.</span></div></div><div><h3>Conclusions</h3><div>This combination therapy has led to good outcomes in patients with advanced oral cancer and lymph node metastases.</div></div>","PeriodicalId":45034,"journal":{"name":"Journal of Oral and Maxillofacial Surgery Medicine and Pathology","volume":"37 6","pages":"Pages 1196-1202"},"PeriodicalIF":0.4000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Thermochemoradiation therapy using retrograde superselective intra-arterial infusion for patients with cervical lymph node metastases from advanced oral squamous cell carcinoma: A retrospective study of 66 cases\",\"authors\":\"Toshiyuki Koizumi , Takashi Ohya , Masaki Iida , Yuichiro Hayashi , Senri Oguri , Toshinori Iwai , Mitomu Kioi , Kenji Mitsudo\",\"doi\":\"10.1016/j.ajoms.2025.06.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><div>A retrospective study of 66 patients with oral squamous cell carcinoma<span><span> was conducted, focusing on the outcomes and treatment-related adverse events of retrograde superselective intra-arterial </span>chemoradiotherapy<span> combined with hyperthermia on metastatic lymph nodes.</span></span></div></div><div><h3>Methods</h3><div><span>The superficial temporal and occipital arteries were catheterized. The treatment consisted of superselective intra-arterial chemotherapy (docetaxel, 60 mg/m</span><sup>2</sup><span>; cisplatin, 150 mg/m</span><sup>2</sup><span>) and daily concurrent radiotherapy (60 Gy) combined with hyperthermia for 6 weeks. Hyperthermia was induced once or twice weekly for 50 min during chemoradiotherapy.</span></div></div><div><h3>Results</h3><div>The 3-year locoregional control and overall survival<span><span> rates were 82 % and 78 %, respectively. Treatment-related adverse events included grade 3 and 4 oral mucositis in 97 % of patients, </span>radiation dermatitis in 50 %, and grade 1 and 2 neck skin burns in 59 % of patients.</span></div></div><div><h3>Conclusions</h3><div>This combination therapy has led to good outcomes in patients with advanced oral cancer and lymph node metastases.</div></div>\",\"PeriodicalId\":45034,\"journal\":{\"name\":\"Journal of Oral and Maxillofacial Surgery Medicine and Pathology\",\"volume\":\"37 6\",\"pages\":\"Pages 1196-1202\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Oral and Maxillofacial Surgery Medicine and Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2212555825001279\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"DENTISTRY, ORAL SURGERY & MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral and Maxillofacial Surgery Medicine and Pathology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212555825001279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
Thermochemoradiation therapy using retrograde superselective intra-arterial infusion for patients with cervical lymph node metastases from advanced oral squamous cell carcinoma: A retrospective study of 66 cases
Objective
A retrospective study of 66 patients with oral squamous cell carcinoma was conducted, focusing on the outcomes and treatment-related adverse events of retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia on metastatic lymph nodes.
Methods
The superficial temporal and occipital arteries were catheterized. The treatment consisted of superselective intra-arterial chemotherapy (docetaxel, 60 mg/m2; cisplatin, 150 mg/m2) and daily concurrent radiotherapy (60 Gy) combined with hyperthermia for 6 weeks. Hyperthermia was induced once or twice weekly for 50 min during chemoradiotherapy.
Results
The 3-year locoregional control and overall survival rates were 82 % and 78 %, respectively. Treatment-related adverse events included grade 3 and 4 oral mucositis in 97 % of patients, radiation dermatitis in 50 %, and grade 1 and 2 neck skin burns in 59 % of patients.
Conclusions
This combination therapy has led to good outcomes in patients with advanced oral cancer and lymph node metastases.